Antibody-based therapies have emerged as powerful tools in the fight against cancer, providing targeted treatment options with reduced side effects. To further enhance their efficacy, researchers have been exploring the use of drug delivery systems (DDS) for the controlled release of antibodies. DDS would produce various benefits in drug efficacy, including improved convenience, reduced toxicity, and enhanced treatment outcomes.1 With the advancement of nanotechnology and increasing focus on antibody-related dosage forms, the development of advanced antibody delivery systems holds promise for cancer patients.
Typically, antibody-based drugs are administered through intravenous routes, although there are risks with infusion-related reactions. To improve patient medication convenience, DDSs controlled release may use strategies such as subcutaneous injections, local depot formulations, inhalation powders, and oral systems.2 Another example are hydrogels, which studies have shown to be a potential DDS, controlling the release of antibody-streptavidin conjugates from the agarose-desthiobiotin hydrogels via controlled dissolution of sparingly soluble biotin derivatives.3
At Biointron, we are dedicated to accelerating antibody discovery, optimization, and production. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.
Chen, Z., Kankala, R. K., Yang, Z., Li, W., Xie, S., Li, H., Chen, Z., & Zou, L. (2022). Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects. Theranostics, 12(8), 3719-3746. https://www.thno.org/v12p3719.htm
Ibeanu, N., Egbu, R., Onyekuru, L., Javaheri, H., Khaw, P. T., Williams, G. R., Brocchini, S., & Awwad, S. (2020). Injectables and Depots to Prolong Drug Action of Proteins and Peptides. Pharmaceutics, 12(10). https://www.mdpi.com/1999-4923/12/10/999
Huynh, V., & Wylie, R. G. (2018). Competitive Affinity Release for Long-Term Delivery of Antibodies from Hydrogels. Angewandte Chemie International Edition, 57(13), 3406-3410. https://onlinelibrary.wiley.com/doi/10.1002/anie.201713428
Biointron announces limited-time RushData launch pricing for high-throughput ant……
Antibody discovery often begins with a highly diverse population of B cells, onl……
As larger candidate panels move from computational design into the laboratory, a……
The idea of single-cell technology is to examine B cells individually. Droplet ……
You can also contact us on the Scientist and Science Exchange marketplaces.